CITIC to sell stake in McDonald's China, Hong Kong business for $430.3 mln-March 2024-www.financetom.com

CITIC to sell stake in McDonald's China, Hong Kong business for $430.3 mln

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

CITIC to sell stake in McDonald's China, Hong Kong business for $430.3 mln

Oct 21, 2024 3:21 AM

Oct 21 (Reuters) - China's state-owned CITIC Ltd ( CTPCF )

has agreed to sell its 19.23% stake in Fast Food

Holdings, the company behind McDonald's China and Hong Kong

operations, to Trustar Fast Food Holdings for $430.3 million.

(Reporting by Roshan Thomas in Bengaluru; Editing by Arun

Koyyur)

Previous page： Sector Update: Consumer Next page： Comcast, Warner Bros Extend Partnership With Multi-Year Distribution Deal

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Sector Update: Consumer

Dec 9, 2024

01:28 PM EST, 12/09/2024 (MT Newswires) -- Consumer stocks were mixed Monday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) up 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) easing 0.1%. In corporate news, Mondelez International ( MDLZ ) is exploring an acquisition of Hershey (HSY) that would create a company with combined sales of nearly...

Comcast, Warner Bros Extend Partnership With Multi-Year Distribution Deal

Dec 9, 2024

01:26 PM EST, 12/09/2024 (MT Newswires) -- Comcast ( CMCSA ) reached long-term agreements to distribute Warner Bros Discovery ( WBD ) content to Xfinity subscribers in the US and Sky customers in the UK and Ireland, the companies said Monday in a joint statement. The partnership will continue to see Warner Bros Discovery ( WBD ) channels including TNT,...

Rigel Pharmaceuticals Reports Initial Efficacy, Safety Data from Cancer Drug Study

Dec 9, 2024

01:32 PM EST, 12/09/2024 (MT Newswires) -- Rigel Pharmaceuticals ( RIGL ) said Monday R289 showed promising initial efficacy and safety data in its ongoing phase 1b study evaluating safety and tolerability in patients with relapsed or refractory lower-risk myelodysplastic syndrome. The drug candidate has demonstrated evidence of transfusion independence in elderly patients, Chief Medical Officer Lisa Rojkjaer said. The...

Poseida Therapeutics Says New Data Support Potential of Allogeneic Cell Therapy Platform

Dec 9, 2024

01:40 PM EST, 12/09/2024 (MT Newswires) -- Poseida Therapeutics ( PSTX ) said Monday it is presenting new data analysis of potential allogeneic cell therapy P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma as well as new preclinical data supporting P-CD19CD20-ALLO1's anti-cancer profile. Interim clinical data from its phase 1 trial of P-BCMA-ALLO1 showed a 91% overall response rate in the...